key: cord-0031775-wsz0r06b
authors: Hiyoshi, Takumi; Domon, Hisanori; Maekawa, Tomoki; Tamura, Hikaru; Isono, Toshihito; Hirayama, Satoru; Sasagawa, Karin; Takizawa, Fumio; Tabeta, Koichi; Terao, Yutaka
title: Neutrophil elastase aggravates periodontitis by disrupting gingival epithelial barrier via cleaving cell adhesion molecules
date: 2022-05-17
journal: Sci Rep
DOI: 10.1038/s41598-022-12358-3
sha: 67d8d8f05d3339d1102ce8b6b131c5f81a9b81a9
doc_id: 31775
cord_uid: wsz0r06b

Neutrophil elastase (NE) functions as a host defense factor; however, excessive NE activity can potentially destroy human tissues. Although NE activity is positively correlated to gingival crevicular fluid and clinical attachment loss in periodontitis, the underlying mechanisms by which NE aggravates periodontitis remain elusive. In this study, we investigated how NE induces periodontitis severity and whether NE inhibitors were efficacious in periodontitis treatment. In a ligature-induced murine model of periodontitis, neutrophil recruitment, NE activity, and periodontal bone loss were increased in the periodontal tissue. Local administration of an NE inhibitor significantly decreased NE activity in periodontal tissue and attenuated periodontal bone loss. Furthermore, the transcription of proinflammatory cytokines in the gingiva, which was significantly upregulated in the model of periodontitis, was significantly downregulated by NE inhibitor injection. An in vitro study demonstrated that NE cleaved cell adhesion molecules, such as desmoglein 1, occludin, and E-cadherin, and induced exfoliation of the epithelial keratinous layer in three-dimensional human oral epithelial tissue models. The permeability of fluorescein-5-isothiocyanate-dextran or periodontal pathogen was significantly increased by NE treatment in the human gingival epithelial monolayer. These findings suggest that NE induces the disruption of the gingival epithelial barrier and bacterial invasion in periodontal tissues, aggravating periodontitis.

Periodontitis is a bacteria-induced inflammatory disease that leads to tooth loss. The etiology of this disease is the bacterial load in the human oral cavity. However, it is clear that the host inflammatory response to microbial challenge causes periodontal tissue destruction 1 . The ideal host response is that microbial stress is eliminated and the tissue returns to a homeostatic state, which is defined by an absence of inflammation. If the resolution process of inflammation fails, a tissue-injurious inflammatory state is triggered 2 . Since the goal of interventions is the return of tissue to homeostasis 3 , therapeutic strategies targeting inflammation are essential to treat periodontitis.

The initial response to acute periodontal inflammation is the physiological response to the oral microbial challenge to recruit leukocytes to sites of infection 3 . Neutrophils are required for homeostatic immunity and contribute to a clinically healthy periodontal tissue; however, supernumerary migration of neutrophils to periodontal tissue can cause tissue damage through the release of inflammatory molecules and tissue-degrading proteases in periodontitis 4 .

Neutrophil elastase (NE) is an abundant proteinase stored in the azurophilic granules of neutrophils and is an indicator of neutrophil activity. NE degrades microbiological components in conjunction with phagocytosis, acting as a host defense mechanism 5 . NE works immunologically only in the cells of neutrophils, whereas excessive NE activity damages host tissues by proteolytic function. Inflammatory lung diseases are characterized by uncontrolled high NE levels, and NE inhibitors have shown some clinical benefits and reduce inflammation 6 . In experimental gingivitis in humans, NE levels were increased in the gingival crevicular fluid, and removal of www.nature.com/scientificreports/ dental plaque decreased the enzyme levels 7 . Additionally, patients with periodontitis showed a positive correlation between NE activity in the gingival crevicular fluid and clinical attachment loss 8 . Our previous study revealed that NE caused detachment and death of human gingival cells after leukotoxin-dependent neutrophil death and NE leakage from inside dead neutrophils 9 .

In this study, we hypothesized that high levels of NE activity caused by an inflammatory response against oral bacteria aggravates periodontitis. We examined the NE activity in periodontal tissue in a ligation-induced murine model of periodontitis. Moreover, we investigated the effects of NE inhibitors on alveolar bone loss, bacterial load, and proinflammatory cytokine gene transcription in the gingiva in a murine model. Furthermore, we evaluated whether NE cleaves cell adhesion molecules and induces the disruption of the gingival epithelial barrier and expansion of bacterial infection in human oral epithelial tissue models in vitro.

Recruitment of neutrophils results in the increase of NE activity in the inflamed gingiva. NE activity in the gingival crevicular fluid is positively correlated with clinical attachment loss 8 . Therefore, we first analyzed the localization of neutrophils and NE in a ligature-induced murine model of periodontitis. As shown in Fig. 1A , lymphocyte antigen 6 complex locus G (Ly6G; neutrophils, red) and NE (green) in the periodontal ligament of the ligated group were higher than those in the unligated group. Additionally, NE activity in the gingival tissue was significantly elevated by tooth ligation (Fig. 1B) . Furthermore, NE activity was significantly lower in the NE inhibitor-injected group than in the uninjected group (Fig. 1B) . NE inhibitor attenuates the periodontal bone loss induced by tooth ligation. We next investigated the protective effect of the NE inhibitor against periodontal bone loss. Figure 2A and B shows that tooth www.nature.com/scientificreports/ ligation induced significant bone loss compared with the unligated group, and NE inhibition significantly attenuated bone loss compared with the ligated group. The number of tartrate-resistant acid phosphatase (TRAP)positive osteoclasts on the surface of the alveolar bone in the ligated group was also higher than that in mice from the unligated group ( Fig. 2C and D). The injection of the NE inhibitor significantly reduced the number of osteoclasts in the bone tissue sections, which was in agreement with the bone loss measurements.

NE inhibitor downregulates the transcription of proinflammatory cytokine gene induced by tooth ligation. Excessive host immunity against microbes is an essential factor in the progression of periodontal disease 10 . Therefore, we next investigated whether injection of an NE inhibitor modulates the transcription of proinflammatory cytokines in the gingiva. Figure 3 shows that the mRNA transcription of Il6, Il1b, and Cxcl1 significantly increased in the gingiva of the ligated group compared with that in the gingiva of the unligated group. Additionally, the transcription of Il6 and Il1b was significantly downregulated in the gingiva of the NE inhibitor-injected group compared with that in the uninjected group. In contrast, the injection of NE inhibitor induced no significant difference in total bacterial load in the ligature under both aerobic and anaerobic conditions (Supplemental Fig. S1 ). These findings suggest that NE inhibitors downregulate Il6 and Il1b cytokines without affecting the bacterial number.

Gingival epithelial cells play a crucial role in the progression of periodontitis by acting as a physical barrier between the outside environment and host 11 . However, NE has been reported to induce detrimental effects on the human nasal mucosal barrier with increased permeability, allowing for potential bacterial invasion 12 . Therefore, we investigated whether NE induces the disruption of periodontal epithelial tissue using three-dimensional human oral epithelial tissue models in vitro. As shown in Fig. 4A , NE induced exfoliation of the gingival epithelial keratinous layer with cell-cell adhesion disruption. Furthermore, NE decreased the expression level of desmoglein 1 (DSG1), a cell adhesion molecule, on the exfoliated epithelial keratinous layer compared with the unligated group (Fig. 4B ). Figure 4C shows that recombinant DSG1 was cleaved by 100 mU/ mL of NE. Furthermore, NE also cleaved other cell adhesion molecules, occludin, and E-cadherin (Fig. 4D ). Figure S2 shows that NE treatment did not induce a significant decrease in bacterial viability against periodontal pathogen used in this study at concentrations of up to 100 mU/ mL, except for F. nucleatum.

This study revealed that neutrophil recruitment and NE activity in inflamed periodontal tissue increased in a ligation-induced murine model of periodontitis. Additionally, NE inhibition decreased alveolar bone loss and transcription of proinflammatory cytokine genes but did not affect the bacterial load in ligatures. An in vitro study suggested that NE disrupts the gingival epithelial barrier by degrading cell adhesion molecules, allowing periodontal pathogen to penetrate the periodontal tissues. These findings suggest that the disruptive effect of NE on the gingival epithelial barrier aggravates periodontitis via the expansion of bacterial infection. Neutrophils are major effectors of infection defense and play an important role in tissue injury. In periodontitis, a large number of neutrophils infiltrate the gingival tissue and sulcus and can eliminate a wide variety of www.nature.com/scientificreports/ bacteria via multiple mechanisms 2,13 . However, it has been reported that the number of neutrophils correlates positively with periodontitis severity 14 . Furthermore, clinical evidence indicates that neutrophils are responsible for a substantial portion of the inflammatory tissue destruction 15 . Consistent with these studies, neutrophil levels in the periodontal ligament were increased in a ligature-induced murine model of periodontitis with significant periodontal bone loss in the present study. The positive/negative effects of neutrophils on periodontitis have not been fully elucidated; thus, the complicated role of neutrophils in periodontitis should be investigated further. Excessive extracellular NE, released from neutrophils by bacteria and their products, induces host tissue damage and periodontal bone destruction 16 . Accordingly, NE activity must be tightly regulated by blood plasmaderived and tissue-derived protease inhibitors to maintain homeostasis. In the gingiva without inflammation, intrinsic antiprotease capacity overwhelms NE activity 17 . However, in patients with periodontitis, NE activity is increased in the gingival crevicular fluid 18 . One reason for this is that some periodontal pathogens stimulate the release of NE while escaping from host-derived proteases by producing protease inhibitors. The outer membrane component of Treponema denticola can trigger protease release from neutrophil azurophilic granules 19 . Additionally, P. gingivalis degrades elastase-specific protease inhibitors, such as elafin, and secretory leukocyte peptidase inhibitors, by producing proteolytic enzymes 20 . A clinical study also reported that NE activity in the gingival crevicular fluid was positively associated with the counts of periodontal pathogen, including P. gingivalis, A. actinomycetemcomitans, Tannerella forsythia, and T. denticola 21 . Furthermore, this study revealed that NE activity, inducing periodontal tissue damage, exhibited minimum bactericidal activity against periodontal pathogen. These findings suggest that extracellular NE is exploited by periodontal pathogen as an etiological agent, rather than NE, which controls infection in periodontitis.

Sivelestat is an NE inhibitor that is selective, reversible, and competitive against NE. The NE inhibitor has been approved clinically for the treatment of patients with acute lung injury associated with systemic inflammatory response syndrome and is useful in such patients 22 . The NE inhibitor also showed clinical benefit in acute respiratory distress syndrome characterized by massive infiltration of neutrophils, monocytes, and lymphocytes 23 . These studies suggest that NE inhibition could be a potential treatment for inflammatory diseases with neutrophil recruitment, including periodontitis. Additionally, considering an increase in antimicrobial-resistant bacteria, which is a major global public health problem, reducing the consumption of antimicrobials and developing alternatives to antimicrobials used in periodontitis is necessary 24 . In this study, the inhibition of NE activity in periodontal tissue suppressed the transcription of proinflammatory cytokine genes and alveolar bone loss. Despite limitations of animal-based models in predicting human responses and the challenges in clinical application, NE inhibitors could be applied as a novel and non-antibiotic therapeutic treatment in periodontitis. www.nature.com/scientificreports/ Cell adhesion molecules play key roles in stabilizing the gingival epithelial barrier and bacterial invasion 25, 26 . It has been reported that P. gingivalis gingipains disrupt the barrier function of stratified squamous epithelium via degradation of cell adhesion molecules, allowing bacterial virulence factors to penetrate subepithelial tissues 27 . Additionally, A. actinomycetemcomitans also disrupts the gingival epithelial barrier by cytolethal distending toxin inducing the subsequent penetration of exogenous pathogens into the host tissues 28 . Penetrated bacterial products induce degradation of the connective tissue and bone, damaging the supporting structures of the teeth. Therefore, early disruption of the epithelial barrier in the development of periodontal disease has significant consequences for oral health 29 . When the bacterial load is low, neutrophils act as a barrier within the gingival crevice, preventing the passage of bacteria deeper into the subjacent gingival connective tissue 16 . However, excessive neutrophils have been reported to disrupt the pulmonary or endothelial epithelial barrier [30] [31] [32] . Nonetheless, the mechanism by which excessive neutrophils injure the gingival epithelial barrier is yet to be clarified. In addition, it was reported that NE inhibitor decreases endotoxemia by improving intestinal permeability and intestinal inflammatory response 33 ; however, the positive effect of NE inhibitor on periodontitis has rarely been reported. In this study, NE cleaved cell adhesion molecules and increased gingival epithelial cell monolayer permeability of periodontal pathogen in vitro. Furthermore, the injection of an NE inhibitor downregulated the transcription of proinflammatory cytokine genes in a murine model of periodontitis. These findings indicate that NE leaking from neutrophils aggravates periodontitis by disrupting the gingival epithelial barrier by cleaving cell adhesion molecules and inducing the invasion of periodontal pathogen. Furthermore, NE inhibitors could suppress the damaging effect of NE and eventually prevent aggravation of periodontitis induced by excessive inflammation in vivo.

Our study has some limitations. The injection of an NE inhibitor downregulated the transcription of proinflammatory cytokine genes in the gingiva, however, we could not evaluate the protein levels of proinflammatory cytokines by ELISA. This may be due to low cytokine levels in the gingiva or interference with detection of the cytokines by blood in the gingiva. Therefore, it is unclear whether NE inhibitor truly reduce inflammatory cytokine proteins in the murine model of periodontitis. Another limitation of this study is that Ca9-22 cell, one of the cancer cell lines, were used to determine the disruptive effect of NE on the gingival epithelial barrier. To be precise, the properties of cancer cell lines are different from primary cells. Thus, it is necessary to validate the effect of the NE and NE inhibitor on periodontal epithelial barrier by in vitro study with primary gingival epithelial cells and in vivo study. We also discuss the limitations that the composition of the oral microbiota have not been revealed in this study. Because NE exhibited minimum bactericidal activity against periodontal pathogen, it has the potential to induce compositional changes that causes periodontitis severity. In addition, it was reported that administration of NE inhibitor in septic rats improved gut microbiota composition 34 . The composition of the oral microbiota closely related to the severity of periodontitis 35 , thus, further studies are required to determine the effects of NE and NE inhibitors on the oral microbiota.

In summary, our study demonstrated that the disruptive effect of NE on the gingival epithelial barrier induces bacterial invasion in periodontal deep tissues, aggravating periodontitis. Additionally, NE inhibitor treatment decreased the transcription of proinflammatory cytokine genes and alveolar bone loss in periodontitis. Thus, NE inhibitor application has potential as a local therapeutic strategy for the treatment of periodontitis.

Mice and reagents. The minimum number of male BALB/c mice (45 mice in total) was purchased from Nihon Chemical Co., Ltd. (Tokyo, Japan), maintained under our institutional guidelines, and subjected to experiments at 8 weeks of age. Sterile feed and water were provided ad libitum. All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of Niigata University (approval no.: SA00451). In addition, the animal experiments were in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. We confirmed that all experiments were performed in accordance with relevant guidelines and regulations. NE inhibitor, sivelestat, was purchased from Ono Pharmaceutical Co., Ltd (Osaka, Japan) and dissolved in phosphate-buffered saline (PBS) at a concentration of 10 mg/mL. Human NE (Innovative Research, Novi, MI, USA) was diluted to an appropriate concentration with 0.1 M Tris-HCl buffer (pH 8.0) containing 0.5 M NaCl.

Tooth ligature-induced murine model of periodontitis. A tooth ligature-induced murine model of periodontitis was established as previously described 36 . Briefly, mice randomly divided and anesthetized with 2-3% isoflurane through a nose mask were ligated with a 5-0 silk ligature around the maxillary second molar to induce periodontitis. The sample size (5 mice per group for each experiment) was set as in the previous study 37, 38 . Ligation was performed on one mouse from each group in turn to minimize potential confounders. Thereafter, 50 μg NE inhibitor in 5 μL PBS (ligature + NE inhibitor group) or 5 μL PBS was injected into the palatal gingiva of the molar once daily for 3 days for the NE activity assay or 7 days for other analyses. A criterion was set that mice with unraveled ligature will be excluded. No mice were excluded from the study. All animal experiments were conducted that the researcher who analyzed the results was blinded from the actual experiment. The humane endpoint was decided as ≥ 20% reduction in body weight from baseline or signs of intense pain. NE activity assay. Three hours after the last injection of NE inhibitor or PBS, the palatal gingival tissues were homogenized in Tris-HCl buffer using BioMasher (Nippi, Tokyo, Japan). These samples were centrifuged at 200 g for 5 min, and NE activity in the supernatant was determined by a method using the NE-specific substrate N-methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide (Merck Millipore, Billerica, MA, USA), as previously described 39 . www.nature.com/scientificreports/ Measurement of periodontal bone loss. Mouse maxillae were imaged using a stereoscopic microscope (× 20) . Periodontal bone loss was calculated according to a previously described method 36 . Briefly, the distance from the cemento-enamel junction to the alveolar bone crest around the ligated second molar was calculated at five points, and the total values were defined as periodontal bone loss (Supplemental Fig. S3 ).

Histological analysis. The maxillae prepared from the murine model were fixed in 4% paraformaldehyde solution (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) for 24 h. The specimens were decalcified in decalcifying solution B (FUJIFILM Wako Pure Chemical Corporation) for 8 days at 4 °C. The specimens were then embedded in an optimal cutting temperature compound (Sakura Finetek Japan Co., Ltd., Tokyo, Japan) and snap-frozen in liquid nitrogen. The prepared coronal sections (10 μm) were stained with TRAP (FUJIFILM Wako Pure Chemical Corporation) according to the manufacturer's instructions and then observed using a BIOREVO BZ-9000 microscope (KEYENCE, Osaka, Japan). On the obtained images, all the TRAP-positive multinucleated giant cells in the periodontal ligament of ligated second molar were counted in five random coronal sections of each mouse.

Immunofluorescence analysis. NE and Ly6G expressions in coronal frozen sections were assessed by immunofluorescence with antibodies specific for NE (Abcam, Cambridge, UK) and Ly6G (Abcam). After overnight incubation with the primary antibody at 4 °C, NE and Ly6G were visualized using Alexa Fluor 488-conjugated anti-rabbit secondary antibody (Invitrogen, Carlsbad, CA) and Alexa Fluor 594-conjugated anti-rat secondary antibody (Invitrogen), respectively. Nuclei were identified using a mounting medium containing 4′,6-diamidino-2-phenylindole (Abcam). The sections were then observed using a confocal laser scanning microscope (Carl Zeiss, Jena, Germany). Disruption assay of three-dimensional human oral epithelial tissue models. Three-dimensional human oral epithelial tissue models with the stratum corneum (SkinEthic HEG; Episkin, Lyon, France) were cultured according to the manufacturer's instructions. Each insert dish with the tissue was transferred to a 24-well plate previously filled with 300 μL of maintenance medium. NE was added to an insert dish at a concentration of 100 mU/mL, followed by incubation at 37 °C in 95% air and 5% CO 2 for 12 h. Thereafter, the tissue models were carefully removed from the insert dish together with the polycarbonate filter. The tissue models were then embedded in an optimal cutting temperature compound (Sakura Finetek Japan Co., Ltd.) and snap-frozen in liquid nitrogen, and frozen sections (20 μm) were prepared in a cryostat. These sections were stained with hematoxylin-eosin (Sakura Finetek) and imaged using a BIOREVO BZ-9000 microscope (KEYENCE).

Proteolytic cleavage analysis. Recombinant human (rh) DSG1 (Abcam), rh-occludin (RayBiotech Inc.

Norcross, GA, USA), and rh-E-cadherin (Abcam) were treated with various NE concentrations (10-100 mU/ mL) at 37 °C for 3 h. Subsequently, samples were separated by SDS-PAGE. DSG1 was detected by western blotting using an anti-DSG1 antibody (Abcam). Occludin and E-cadherin were detected by staining with Coomassie Brilliant Blue (Apro Science, Tokushima, Japan).

Gingival epithelial cell permeability assay. The human gingival epithelial cell line Ca9-22 was grown using a previously described method 40 . The cells were seeded on the upper compartments of 0.4-μm (for FITCdextran) or 1-μm (for periodontal pathogen) pore-size Transwell (Corning, NY, USA, and Merck Millipore, respectively) at a density of 1 × 10 5 cells per well and were cultured for 3 days to form epithelial monolayers. NE was added to the upper compartments at concentrations of up to 100 mU/mL. After 3 h of incubation, the medium in the upper compartments was removed, and 70 kDa of FITC-dextran (100 μg/mL, Cosmo Bio, Tokyo, Japan) or suspensions of Porphyromonas gingivalis strain ATCC 33277, Aggregatibacter actinomycetemcomitans strain JP2, Fusobacterium nucleatum strain ATCC 25586, and Prevotella intermedia strain ATCC 25611 were added. After 3 h, the medium was collected from the lower chamber compartments of each group. In the FITC-dextran-added group, the fluorescence intensity of the medium was measured using a GloMax microplate reader (Promega, Madison, WI, USA) at 485-nm excitation and 520-nm emission wavelength. In the bacterial suspension-added group, 100 μL of the medium was plated onto 5% sheep blood agar plates, and bacterial permeability was determined using the colony counting method.

Statistical analysis. Data were analyzed using GraphPad Prism 7.03 (GraphPad Software, Inc., La Jolla, CA, USA). Significant differences were tested using one-way analysis of variance with Tukey's multiple comparison method or Dunnett's multiple comparison method.

Periodontitis: A polymicrobial disruption of host homeostasis

Resolution of inflammation in periodontitis: A review

Inflammatory and immune pathways in the pathogenesis of periodontal disease

New developments in neutrophil biology and periodontitis

Host-derived diagnostic markers for periodontitis: Do they exist in gingival crevice fluid

The role of neutrophils and neutrophil elastase in pneumococcal pneumonia

Neutrophil elastase and its inhibitors in human gingival crevicular fluid during experimental gingivitis

Long-term monitoring of adult periodontitis patients in supportive periodontal therapy: Correlation of gingival crevicular fluid proteases with probing attachment loss

Aggregatibacter actinomycetemcomitans induces detachment and death of human gingival epithelial cells and fibroblasts via elastase release following leukotoxin-dependent neutrophil lysis

Periodontitis: From microbial immune subversion to systemic inflammation

The maintenance of an oral epithelial barrier

The effect of neutrophil serine proteases on human nasal epithelial cell barrier function

Neutrophil recruitment and function in health and inflammation

Quantifying oral inflammatory load: Oral neutrophil counts in periodontal health and disease

Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in-vivo-Role of active enzyme in human periodontitis

Oral inflammatory load: Neutrophils as oral health biomarkers

SLPI and elafin: One glove, many fingers

Proteomics-The research frontier in periodontics

Membrane components of Treponema denticola trigger proteinase release from human polymorphonuclear leukocytes

Differential effects of periopathogens on host protease inhibitors SLPI, elafin, SCCA1, and SCCA2

Periodontal pathogens affect the level of protease inhibitors in gingival crevicular fluid

Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study

Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19

AMR-intervene: A social-ecological framework to capture the diversity of actions to tackle antimicrobial resistance from a One Health perspective

Cell adhesion proteins: Roles in periodontal physiology and discovery by proteomics

Azithromycin recovers reductions in barrier function in human gingival epithelial cells stimulated with tumor necrosis factor-alpha

Porphyromonas gingivalis induces penetration of lipopolysaccharide and peptidoglycan through the gingival epithelium via degradation of junctional adhesion molecule 1

Breaking the gingival epithelial barrier: Role of the Aggregatibacter actinomycetemcomitans cytolethal distending toxin in oral infectious disease

Epithelial barrier and oral bacterial infection

Streptococcus pneumoniae disrupts pulmonary immune defence via elastase release following pneumolysindependent neutrophil lysis

Neutrophils from critically ill septic patients mediate profound loss of endothelial barrier integrity

Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1

Sivelestat alleviates atherosclerosis by improving intestinal barrier function and reducing endotoxemia. Front. Pharmacol

Positive effects of neutrophil elastase inhibitor (Sivelestat) on gut microbiome and metabolite profiles of septic rats

The role of the microbiota in periodontal disease

Analysis of experimental ligature-induced periodontitis model in mice

Protective effect of hinokitiol against periodontal bone loss in ligature-induced experimental periodontitis in mice

Effects of erythromycin on osteoclasts and bone resorption via DEL-1 induction in mice

Neutrophil elastase subverts the immune response by cleaving toll-like receptors and cytokines in pneumococcal pneumonia

Antibacterial activity of hinokitiol against both antibiotic-resistant and -susceptible pathogenic bacteria that predominate in the oral cavity and upper airways

This study was supported by JSPS KAKENHI (Grant Numbers: JP21K21058, JP20K21671, JP20H03858, JP20K09903, JP19K22706, and JP19H03828) and Kobayashi International Scholarship Foundation.

T.H. and H.D. contributed to the conception, design, data acquisition, analysis, and interpretation, performed all statistical analyses, and drafted and critically revised the manuscript. T.M., H.T., T.I., S.H., K.S., and F.T. contributed to the design, data acquisition, analysis, and critically revised the manuscript. K.T. and Y.T. provided guidance; contributed to conception, design, date analysis, and interpretation, and drafted and critically revised the manuscript. All authors gave their final approval and agreed to be accountable for all aspects of the work.

The authors declare no competing interests.

Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-022-12358-3.Correspondence and requests for materials should be addressed to Y.T.Reprints and permissions information is available at www.nature.com/reprints.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.